DAROLUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC): ARASEC – US PROSPECTIVE, OPEN-LABEL PHASE 2 STUDY WITH AN EXTERNAL CONTROL ARM

McKay, R. R., Ross, A. E., Preston, M. A., Gregg, J. R., Salami, S. S., Saad, F., … Shore, N. D. (2026). DAROLUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC): ARASEC – US PROSPECTIVE, OPEN-LABEL PHASE 2 STUDY WITH AN EXTERNAL CONTROL ARM. Journal of Urology, 215(5S2). https://doi.org/10.1097/01.ju.0001192572.07890.f8.08